BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition
about
Evolutionary determinants of cancerMolecular mechanisms for survival regulation of chronic myeloid leukemia stem cellsFOXO transcription factors throughout T cell biologyCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaAnimal models of leukemia: any closer to the real thing?An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imagingThe DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer CellsPhosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic LeukemiaBCL6 modulation of acute lymphoblastic leukemia response to chemotherapyClonal evolution in cancerMechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell linesRegulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development.Genomic profiling by whole-genome single nucleotide polymorphism arrays in Wilms tumor and association with relapse.In vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice.The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factorsTransient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC.Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemiaRationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.STAT5 is a potent negative regulator of TFH cell differentiation.Bcl6 and Maf cooperate to instruct human follicular helper CD4 T cell differentiation.POK/ZBTB proteins: an emerging family of proteins that regulate lymphoid development and functionDipeptide species regulate p38MAPK-Smad3 signalling to maintain chronic myelogenous leukaemia stem cells.Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.Molecular genetics of B-precursor acute lymphoblastic leukemiaMLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia.Deregulated expression of the HSP40 family members Auxilin-1 and -2 is indicative of proteostasis imbalance and predicts patient outcome in Ph(+) leukemia.Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin.Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy.Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia.All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.Ikaros regulation of the BCL6/BACH2 axis and its clinical relevance in acute lymphoblastic leukemia
P2860
Q26801710-147BEF91-B0C8-45F0-956F-DCAF8876FD1CQ26828528-2B0340E8-8584-4749-9E1A-0C017BED9D3DQ26853741-45291775-E665-497C-8330-DFD2A354098BQ27025242-0FB4BA78-775D-4CCE-8F2A-B03AA306BB5FQ27026520-44107910-29F5-4DA5-8367-CAA0812481E9Q27311229-D0FE79D3-FFB9-4BA2-AA2F-A43BCD2FDC67Q27313466-5C30F3F8-1CF2-4E68-8CF8-682E011A7D3DQ28547880-17499BE6-299C-41C5-AD15-EDA367349699Q28829626-611D7F5E-116E-4D7D-8FA7-0D978DDC26F7Q29547696-AAF86B32-8B95-47F3-90FC-A91AA002ED80Q33694514-870C0A70-3DCE-48B2-83D4-B51AEB7B80B6Q33914049-FAB31F00-8C55-4C6B-8830-5A0DFABA5898Q34159585-4D12055D-0086-47FE-A4C1-AF56C4F18779Q34190897-E5E3529F-13B5-4539-85E1-8308BE6561FFQ34541243-22DE9EBE-4BC7-4D51-88E3-6771E8310EEFQ34806728-FFDD6F44-A08D-4D82-890A-A144463C9876Q35063947-AD0A541D-8EF9-43C2-88F4-EF0336572937Q35273390-496F7780-CAB2-4E5B-8F9F-D3F72317A304Q35441406-07D9CB2C-2DC3-4C8B-9C48-F28EC5C4C537Q35483709-8F196399-C00F-423E-BF7B-FD35A2AA68FAQ35637452-221CBF96-9572-4835-9C74-293D4555EDC4Q35723998-0BEF4BD4-B8D3-417B-A3D3-E4BAB0A81B88Q35761809-884EA3EC-E3AC-49CE-9E0F-08B00474B5FBQ35884238-9D321474-7511-492F-ABEA-9C4934DE4466Q35906761-12012624-79C7-42AA-92B4-801D62A97118Q36030083-1D23F20B-F5A3-4F7A-A5A8-B191C1DCE62DQ36037500-3D64C700-7255-487E-92A0-7FEA636505F2Q36201677-301A4500-20F3-4656-A62C-86BD96F92E43Q36290242-7AC7F6D3-2739-4D96-9FCC-F0CF97A62FFFQ36426910-4A445E49-2511-4109-B2B8-4FE14D212BC5Q36512597-00101AE6-4AEE-4128-ADB2-7A82FCFACCEAQ36560517-682E3D3E-23C4-4665-B79D-3C114F8D3239Q36652029-349D6616-8D4A-4DFA-938F-6409B7EAFA6DQ36666787-90116688-A61C-43CA-99A1-AA4BE51F1B5DQ36697774-32032E6C-81E2-4FD3-AC10-D15F9AC251A9Q36707715-0FE38972-5185-4ECC-9C59-435D951C76A0Q36750016-F8220B05-A23E-4CA0-AEC8-969FF45AB23DQ36989582-B75A0B24-8539-4CB6-B058-EEDF29616DDCQ37554700-952276AC-5C39-40B7-AD17-0E8A911E5C65Q37702652-1C62036D-CAFA-42FA-A6C2-6776360384FF
P2860
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
BCL6 enables Ph+ acute lymphob ...... ive BCR-ABL1 kinase inhibition
@ast
BCL6 enables Ph+ acute lymphob ...... ive BCR-ABL1 kinase inhibition
@en
type
label
BCL6 enables Ph+ acute lymphob ...... ive BCR-ABL1 kinase inhibition
@ast
BCL6 enables Ph+ acute lymphob ...... ive BCR-ABL1 kinase inhibition
@en
prefLabel
BCL6 enables Ph+ acute lymphob ...... ive BCR-ABL1 kinase inhibition
@ast
BCL6 enables Ph+ acute lymphob ...... ive BCR-ABL1 kinase inhibition
@en
P2093
P2860
P50
P356
P1433
P1476
BCL6 enables Ph+ acute lymphob ...... ive BCR-ABL1 kinase inhibition
@en
P2093
Ari Melnick
B Hilda Ye
Christian Hurtz
Cihangir Duy
Eugene Park
H Phillip Koeffler
Hassan Jumaa
Huimin Geng
J Jessica Yu
P2860
P2888
P304
P356
10.1038/NATURE09883
P407
P577
2011-05-01T00:00:00Z